CVR number 30725484
Industry 46.4620 Wholesale of pharmaceutical goods

CANDOR ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  2.7% 1.7% 2.7% 4.8% 2.2%  
Credit score (0-100)  62 74 60 43 66  
Credit rating  BBB A BBB BBB BBB  
Credit limit (kDKK)  0.0 10.4 0.0 0.0 0.1  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Net sales  0 0 0 0 0  
Gross profit  2,690 4,831 4,709 487 1,209  
EBITDA  2,136 4,198 3,930 -209 365  
EBIT  2,135 4,190 3,869 -287 321  
Pre-tax profit (PTP)  2,115.9 4,163.8 3,845.7 -296.7 331.3  
Net earnings  1,648.0 3,247.3 3,000.5 -232.7 259.4  
Pre-tax profit without non-rec. items  2,116 4,164 3,846 -297 331  
 
See the entire income statement

Balance sheet (kDKK) 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Tangible assets total  36.5 60.4 334 149 105  
Shareholders equity total  1,869 5,116 5,117 2,084 2,343  
Interest-bearing liabilities  0.0 173 24.5 0.0 0.0  
Balance sheet total (assets)  2,830 8,890 6,244 2,353 2,857  
Net Debt  -1,354 -4,423 -3,880 -86.7 -115  
 
See the entire balance sheet

Volume 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,690 4,831 4,709 487 1,209  
Gross profit growth  468.7% 79.6% -2.5% -89.7% 148.2%  
Employees  1 2 2 2 2  
Employee growth %  -50.0% 100.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,830 8,890 6,244 2,353 2,857  
Balance sheet change%  148.0% 214.2% -29.8% -62.3% 21.4%  
Added value  2,134.7 4,190.0 3,868.8 -286.9 320.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  35 16 212 -262 -88  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 -1.0 1.0  

Profitability 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  79.4% 86.7% 82.2% -58.9% 26.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  107.5% 71.5% 51.3% -6.5% 12.8%  
ROI %  193.3% 117.0% 74.3% -7.7% 15.0%  
ROE %  157.8% 93.0% 58.6% -6.5% 11.7%  

Solidity 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Equity ratio %  68.0% 60.3% 81.9% 88.6% 82.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -63.4% -105.4% -98.7% 41.4% -31.4%  
Gearing %  0.0% 3.4% 0.5% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  31.6% 30.3% 33.8% 156.6% 0.0%  

Liquidity 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Quick Ratio  2.3 2.1 3.8 2.0 2.4  
Current Ratio  2.9 2.3 5.3 8.2 5.7  
Cash and cash equivalent  1,354.3 4,595.3 3,904.1 86.7 114.6  

Capital use efficiency 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,833.4 5,059.6 4,796.4 1,935.1 2,268.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
Net sales / employee  0 0 0 0 0  
Added value / employee  2,135 2,095 1,934 -143 160  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  2,136 2,099 1,965 -105 182  
EBIT / employee  2,135 2,095 1,934 -143 160  
Net earnings / employee  1,648 1,624 1,500 -116 130